San Diego-based Neurocrine Biosciences, Inc. announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its investigational congenital adrenal hyperplasia (CAH) drug. The agency granted orphan status to NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist for treatment of CAH, a disease that …